Dr. Mark A. Crowe, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University Alabama Birmingham - School of Optometry (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,185
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University Alabama Birmingham - School of Optometry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME87513 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME87513 -
Internal Medicine Physician
FL license ME87513
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Baptist Medical Center Beaches Jacksonville Beach, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
Medical groups
- Respiratory Critical Care and Sleep Medicine Associates,inc (41 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,185
- Services billed
- 3,792
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 539 | 292 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 190 | 29 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 176 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 145 | 63 |
| Established patient office or other outpatient visit, 20-29 minutes | 125 | 115 |
| Critical care, first 30-74 minutes | 123 | 61 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 50 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 59 | 19 |
| Test to examine how well the lungs exchange gases | 59 | 59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 39 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Jacksonville, FL | 182 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Jacksonville, FL | 164 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Jacksonville, FL | 110 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Jacksonville, FL | 107 |
| Prednisone Other prescribers in Jacksonville, FL | 57 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Jacksonville, FL | 48 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Jacksonville, FL | 33 |
| Fluticasone Propionate Other prescribers in Jacksonville, FL | 31 |
| Ipratropium Bromide Other prescribers in Jacksonville, FL | 31 |
| Montelukast Sodium Other prescribers in Jacksonville, FL | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 62 payments worth $1,525 in total to this clinician.
| GlaxoSmithKline, LLC. | $210 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $185 |
| Genzyme Corporation | $148 |
| Actelion Pharmaceuticals US, Inc. | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | $117 |
| Viatris Specialty LLC | $78.90 |
| United Therapeutics Corporation | $75.58 |
| Axsome Therapeutics, Inc. | $74.52 |
| Food and Beverage | $1,525 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.